Download by
Scanning QR Code
No Stock Yet
Dongwu Securities: Synthetic biology has strong barrier properties and multiple factors drive the rapid development of the industry
The Zhitong Finance App learned that Dongwu Securities released a research report saying that looking at synthetic biology companies from the three dimensions of R&D, product selection, and expanded production, they have integrated R&D platforms, rich application scenarios in the downstream market of selected varieties, and product selection strategies with synergistic effects between products. Companies that expand production capacity and have perfect technology are a benchmark for the industry. Judging from Ginkgo Bioworks, a leading global platform-based synthetic biology company, platform-based synthetic biology companies are active in epitaxial mergers and acquisitions with a view to improving platform capabilities and forming a closed loop of business capabilities. In terms of investment opportunities, it is recommended to focus on providing them under the influence of synthetic biology
CITIC Construction Investment: Medical and aesthetic demand will gradually recover, leading companies are resilient
Investing in Bloomage BioTechnology (SHSE:688363) Three Years Ago Would Have Delivered You a 53% Gain
By buying an index fund, investors can approximate the average market return. But if you pick the right individual stocks, you could make more than that. Just take a look at Bloomage BioTechnology C
Changes in the beauty care sector boosted Bethenny's rise by more than 5%
Huaxi Biotech (688363): Multi-brand building ability verifies healthy growth of functional skincare products
Core view: Foreword: Huaxi Biotech is a diversified biotechnology company whose business covers various categories such as raw materials, medical terminals, and functional skincare products. 22H1's functional skincare revenue was 2.13 billion yuan, an increase of 77.2% over the previous year, accounting for 72.5%, which was the main source of the company's performance growth. This report focuses on its functional skincare business. First, it sorts out the development of the four major brands, and then focuses on the two issues of future growth and profitability of the four major brands. The brand's continued growth comes from underlying technology support
Bank of China Securities: The penetration rate of collagen in the beauty care field is rapidly increasing, leading companies are expected to achieve efficient growth
The Zhitong Finance App learned that Bank of China Securities released a research report stating that benefiting from the development of extraction technology and the promotion of the downstream face value economy, the fields of medical aesthetics, functional skincare products and medical dressings are driving the rapid growth of the collagen industry, and the penetration rate in the beauty care sector has increased rapidly. From the perspective of the industrial chain, high-quality targets cover the middle and lower reaches of the industrial chain, and have strong R&D capabilities and profitability. As policies and regulations are strictly enforced, leading enterprises are expected to achieve efficient growth by relying on their own strong product strength and consumer stickiness. Recommended attention: Huaxi Biotech (688363.SH), Aimei (300896.SZ), Giant Biotech (02367)
Caixin Securities: Consumer demand is expected to bottom up and the valuation of the beauty care sector is the most cost-effective
The Zhitong Finance App learned that Caixin Securities released a research report saying that looking ahead to next year, the relaxation of the epidemic prevention policy is combined with strategies to expand domestic demand, and domestic consumer demand is expected to bottom up and rise. Looking at the industry level, loosening expectations of epidemic prevention boosted the sector's rise. The three major sectors of beauty care, social services, and commercial retail all performed well. Under the impact of the epidemic in 2022, the social services sector's performance improved the most. Currently, the valuation of the beauty care sector is the most cost-effective. In the beauty care sector, trends in the cosmetics industry have been improving for a long time. On the performance side, internal performance is divided, and the certainty of leading core companies continues to be realized. Investment advice: Focus on recommending Aimei
Does Bloomage BioTechnology (SHSE:688363) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
Huaxi Biotech (688363): Four-wheel drive promotes the development of skincare products and is expected to increase profitability
Report summary Huaxi Biotech started in the hyaluronic acid raw materials business. Adhering to the development logic of “science → technology → product → brand”, it has now formed a four-wheel drive business pattern of raw materials business, functional skincare business, medical terminal business, and functional food business. Raw materials business: As a leading global hyaluronic acid raw material company, the company is expected to benefit from 1) capacity expansion. In 2022, the Tianjin plant production line was officially put into operation, adding 300 tons of hyaluronic acid production capacity; 2) Shiseido's sodium hyaluronate raw materials are gradually withdrawn from the pharmaceutical-grade HA market, and the company's international market share is expected
Bloomage BioTechnology Corporation Limited's (SHSE:688363) Largest Shareholders Are Private Equity Firms With 66% Ownership, Individual Investors Own 17%
To get a sense of who is truly in control of Bloomage BioTechnology Corporation Limited (SHSE:688363), it is important to understand the ownership structure of the business. We can see that private e
Loading...
No Stock Yet